PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Last trade$3.84
Day change-$0.35 (-8.35%)
Day range$3.62 – $4.21
Volume4,015,381
Market cap$290M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$290.2M
Price / earnings
—
Price / book
2.82×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.49×
Profitability
Earnings per share
-$1.06
Return on assets
-57.37%
Return on equity
-71.13%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.7×
Quick ratio
8.7×
Cash ratio
1.78×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.28M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PEPG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$5.91M
$6.42M
$5.94M
$5.85M
$5.23M
$5.54M
$5.94M
$5.38M
Research and development
$14.48M
$12.52M
$13M
$13.85M
$13.42M
$18.39M
$25.38M
$18.96M
Total operating expenses
$20.38M
$18.94M
$18.94M
$19.71M
$18.65M
$23.93M
$31.32M
$24.35M
Operating income
-$20.38M
-$18.94M
-$18.94M
-$19.71M
-$18.65M
-$23.93M
-$31.32M
-$24.35M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$19.38M
-$17.8M
-$17.75M
-$18.29M
-$18.03M
-$23.09M
-$30.2M
-$22.86M
Income taxes
$13K
$16K
$15K
$49K
$0
$0
$0
-$617K
Net income
-$19.39M
-$17.81M
-$17.76M
-$18.34M
-$18.03M
-$23.09M
-$30.2M
-$22.24M
Net income attributable to common shareholders
-$19.39M
-$17.81M
-$17.76M
-$18.34M
-$18.03M
-$23.09M
-$30.2M
-$22.24M
EBITDA
-$20.14M
-$18.69M
-$18.62M
-$19.37M
-$18.32M
-$23.6M
-$30.93M
-$23.97M
Basic earnings per share
-$0.28
-$0.26
-$0.26
-$0.27
-$0.52
-$0.70
-$0.92
-$0.68
Diluted earnings per share
-$0.28
-$0.26
-$0.26
-$0.27
-$0.52
-$0.70
-$0.92
-$0.68
Recent news
Company coverage with links to the original publishers.
The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players including Novartis, Oncopeptides, Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen driving innovation through strategic partnerships and technological advancements in peptide design and linker technologies.
U.S. stocks traded lower midday, with the S&P 500 dropping 1%. Accenture reported strong Q4 earnings, beating analyst estimates, while several other companies experienced significant stock price movements.
PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.
A class action lawsuit has been filed against PepGen alleging false and misleading statements about the company's drug PGN-EDO51, its CONNECT2 study effectiveness, and clinical prospects during the period of March 7, 2024 to March 3, 2025.
Law firm announces class action lawsuit against PepGen Inc. for allegedly making false and misleading statements about its drug PGN-EDO51 and clinical study CONNECT2 between March 2024 and March 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.